Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-02-07T06:34:17Z | - |
dc.date.available | 2018-02-07T06:34:17Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.citation | ARCHIVES OF PHARMACAL RESEARCH, v. 38, No. 4, Page. 522-533 | en_US |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://link.springer.com/article/10.1007/s12272-014-0399-0 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/35897 | - |
dc.description.abstract | The purpose of this study was to improve the gastric solubility and bioavailability of rebamipide (RBM) by preparing the RBM solid dispersion tablet (RBM-SDT) from solid dispersion powder prepared by spray-drying technique. For preparation of rebamipide solid dispersions (RBM-SDs), solubility study was performed in various hydrophilic carriers and alkalizers, among which sodium alginate and sodium carbonate were selected as the hydrophilic polymer and alkalizer, respectively. Different combinations of drug-polymer-alkalizer were dissolved in aqueous solution and spray-dried in order to obtain solid dispersions. Noticeable improvement in aqueous solubility (approximately 200 times) and in vitro dissolution rate was observed by RBM-SDs, compared to RBM powder. The optimized formulation of RBM-SD powder consisted of RBM powder/sodium alginate/sodium carbonate at the weight ratio of 1/2/2. The transformation of crystalline RBM to amorphous RBM-SD powder was clearly demonstrated by powder X-ray diffraction, differential scanning calorimetry (DSC) and scanning electron microscopy. The optimized RBM-SD was formulated in tablet dosage form, containing approximately 2 % sodium lauryl sulphate and poloxamer F68 as wetting agents. The RBM-SDT exhibited enhanced dissolution in hydrochloric acid buffer (pH 1.2) and distilled water. Moreover, pharmacokinetic study in rats showed higher AUC and C-max for RBM-SDT than those for RBM powder and commercial product. Thus, the developed RBM-SDT formulation can be more efficacious for improving oral bioavailability of RBM. | en_US |
dc.description.sponsorship | This study was supported by a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013) (No. HT13C0011). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | PHARMACEUTICAL SOC KOREA | en_US |
dc.subject | Rebamipide | en_US |
dc.subject | Solubility | en_US |
dc.subject | Solid dispersion | en_US |
dc.subject | Spray-drying | en_US |
dc.subject | Bioavailability | en_US |
dc.subject | SPRAY-DRYING TECHNIQUE | en_US |
dc.subject | IN-VIVO EVALUATION | en_US |
dc.subject | ENHANCED BIOAVAILABILITY | en_US |
dc.subject | SOLUBLE DRUGS | en_US |
dc.subject | BETA-CYCLODEXTRIN | en_US |
dc.subject | SALT FORM | en_US |
dc.subject | ABSORPTION | en_US |
dc.subject | RELEASE | en_US |
dc.subject | PH | en_US |
dc.subject | INCLUSION | en_US |
dc.title | Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability | en_US |
dc.type | Article | en_US |
dc.relation.no | 4 | - |
dc.relation.volume | 38 | - |
dc.identifier.doi | 10.1007/s12272-014-0399-0 | - |
dc.relation.page | 522-533 | - |
dc.relation.journal | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.contributor.googleauthor | Pradhan, R | - |
dc.contributor.googleauthor | Tran, TH | - |
dc.contributor.googleauthor | Choi, JY | - |
dc.contributor.googleauthor | Choi, IS | - |
dc.contributor.googleauthor | Choi, HG | - |
dc.contributor.googleauthor | Yong, CS | - |
dc.contributor.googleauthor | Kim, JO | - |
dc.relation.code | 2015009399 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.